Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 3
Opinion
Video
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Key Takeaways
- PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions.
- Investigational agents in BCG-naive and unresponsive settings include gene therapy and intravesical treatments, targeting enhanced immune activation.
Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.
Video Player is loading.
Video content above is prompted by the following:
- What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?
- What are their mechanisms of action?
What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?
Related Videos
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Exploring Emerging Data in NMIBC
Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
Related Content
